新型抗凝药物直接Xa因子抑制剂利伐沙班

中国临床药理学与治疗学 ›› 2009, Vol. 14 ›› Issue (4): 361-367.

• 专论 • 下一篇

新型抗凝药物直接Xa因子抑制剂利伐沙班

柯永胜

皖南医学院弋矶山医院心内科, 皖南医学院心血管疾病研究所, 芜湖241001, 安徽

收稿日期:2003-03-04 修回日期:2009-05-19 发布日期:2020-10-29
通讯作者: Tel:0553-5739313 E-mail:kongyoungsheng@163.com
作者简介:柯永胜,男,主任医师,教授。皖南医学院硕士研究生导师(病理生理学、心血管内科学)。在国内外各级刊物发表学术论文130余篇,其中在SCI收录期刊发表学术论文7篇,出版学术专著5部,系安徽省学术与技术带头人、安徽省教育厅学术与技术带头人、安徽省卫生厅学术与技术带头人、国家自然科学基金同行评议专家。Journal of Pharmacology and Experimental Therapeutics、International Journal of Cardiology、Acta Pharmacologica Sinica 、Acta Clin Chemica 、Biochemical Pharmacology 、Journal of the College of Physicians and Surgeons Pakistan 、中国药理学通报、皖南医学院学报等杂志审稿人。中国临床药理学与治疗学杂志编委, 西安交通大学学报医学版特约编委。享受安徽省政府特殊津贴。专业方向:冠心病介入治疗, 心肌缺血再灌注机制研究。

Novel anticoagulant, direct factor Xa inhibitor: Rivaroxaban

KE Yong-sheng

Department of Cardiovascular Disease, Institute of Cardiovascular Disease, Wannan Medical College Affiliated Yijishan Hospital, Wuhu 241001, Anhui, China

Received:2003-03-04 Revised:2009-05-19 Published:2020-10-29

摘要/Abstract

摘要： 抗凝药物在防治血栓事件中发挥重要作用,但传统的抗凝药物如肝素需胃肠道外给药,院外使用不便。口服抗凝药如华法林治疗安全窗窄,需经常监测凝血酶原时间,也给患者使用带来不便。新型口服抗凝剂利伐沙班是直接Xa因子抑制剂,具有使用方便、无需监测的优点。现有的循证医学证据表明其在防治血栓事件中安全、有效。本文就利伐沙班的临床研究进展作一介绍。

关键词: 抗凝药, Xa 因子抑制剂, 利伐沙班, 静脉血栓, 急性冠脉综合征, 房颤

Abstract: Anticoagulants are recommended for the prevention and treatment of a wide variety of thromboembolic events.Although existing anticoagulants are effective , their usage is limited by parenteral administration or the requirement for frequent monitoring and subsequent dose adjustment.Therefore , there is an urgent need for novel , oral agents with a predictable anticoagulant action.Because of its key position in the coagulation cascade and its limited roles outside of coagulation, Factor Xa has presented as an attractive target for novel anticoagulants.As a result , the past decade has witnessed an explosion of research into small-molecule, oral , direct Factor Xa inhibitors , and some are now in clinical development.Rivaroxaban is currently furthest ahead in its developmental program, having entered phase III in 3 indications.It is hoped that , before long , these anticoagulants will allow us to enter an era of convenient , oral anticoagulation , without the need for regular monitoring or dose adjustment.

Key words: anticoagulant, Factor Xa inhibitor, Rivaroxaban, vein thrombosis, acute coronary syndrome, atrial fibrillation

中图分类号:

R973+.2

柯永胜. 新型抗凝药物直接Xa因子抑制剂利伐沙班[J]. 中国临床药理学与治疗学, 2009, 14(4): 361-367.

KE Yong-sheng. Novel anticoagulant, direct factor Xa inhibitor: Rivaroxaban[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(4): 361-367.

参考文献

[1] Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy [J].Chest,2004, 126(3 Suppl):338S-400S.
[2] Ansell J, Hirsh J, Poller L, et al.The pharmacology and management of the vitamin K antagonists:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy[J].Chest, 2004, 126(3 Suppl):204S-233S.
[3] Shimizu T, Nishihira J, Watanabe H, et al.Macrophage migration inhibitory factor is induced by thrombin and factor Xa in endothelial cells[J].J Biol Chem, 2004, 279(14):13729-13737.
[4] Vesey DA, Cheung CW, Kruger WA, et al.Thrombin stimulates proinflammatory and proliferative responses in primary cultures of human proximal tubule cells[J].Kidney Int, 2005, 67(4):1315-1329.
[5] Tarzami ST, Wang G, Li W, et al.Thrombin and PAR-1 stimulate differentiation of bone marrow-derived endothelial progenitor cells[J].J Thromb Haemost, 2006, 4(3):656-663.
[6] Bauer KA.New anticoagulants:anti IIa vs anti Xa-is one better[J]? J Thromb Thrombolysis, 2006, 21(1):67-72.
[7] Hermans C, Claeys D.Review of the rebound phenomenon in new anticoagulant treatments[J].Curr Med Res Opin, 2006, 22(3):471-481.
[8] Turpie AG, Bauer KA, Eriksson BI, et al.Fondaparinuxvs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery:a meta-analysis of 4 randomized double-blind studies [J].Arch Intern Med,2002, 162(16):1833-1840.
[9] Samama MM, Gerotziafas GT, Elalamy I, et al.Biochemistry and clinical pharmcology of new anticoagulant agents[J].Pathophysiol Haemost Thromb, 2002, 32(56):218-224.
[10] Perzborn E, Strassburger J, Wilmen A, et al.In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor[J].J Thromb Haemost, 2005, 3(3):514-521.
[11] Walenga JM, Hoppensteadt D, Iqbal O, et al.The oral,direct factor Xa inhibitor BAY 59-7939 does not cross-react with anti-heparin PF4 (heparin-induced thrombocytopenia)antibodies[J].Blood, 2005, 106:Abstract 1883.
[12] Kubitza D, Becka M, Voith B, et al.Safety, pharmacodynamics,and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor[J].Clin Pharmacol Ther, 2005, 78(4):412-421.
[13] Kubitza D, BeckaM, Wensing G, et al.Safety, pharmacodynamics,and pharmacokinetics of BAY 59-7939-anoral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects[J].Eur J Clin Pharmacol, 2005, 61(12):873-880.
[14] Kubitza D, BeckaM, MueckW, et al.Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban-an oral, direct Factor Xa inhibitor-are not affected by aspirin[J].J Clin Pharmacol, 2006, 46(9):981-990.
[15] Kubitza D, Becka M, Zuehlsdorf M, et al.No interaction between the novel, oral direct Factor Xa inhibitor BAY 59-7939 and digoxin[J].J Clin Pharmacol, 2006, 46:702.
[16] Kubitza D, Mueck W, Becka M.The oral, direct Factor Xa inhibitor BAY 59-7939 does not prolong the QTc interval[J].J Clin Pharmacol, 2006, 46:703.
[17] Eriksson BI, Borris LC, Dahl OE, et al.Rivaroxaban for prevention of venous thromboembolism after hip replacement:a phase IIa proof-of-principle study[J].Pathophysiol Haemost Thromb, 2006, 35:A33.
[18] Eriksson BI, Borris L, Dahl OE, et al.Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement[J].J Thromb Haemost, 2006, 4(1):121-128.
[19] Turpie AG, Fisher WD, Bauer KA, et al.BAY 59-7939:an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement.A phase II dose-ranging study[J].J Thromb Haemost, 2005, 3(11):2479-2486.
[20] The ATLAS ACS TIMI 46 Trial.Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Subjects With Acute Coronary Syndromes[R].AHA 2008 Scientific Sessions ;November 10, 2008, New Orleans, LA.
[21] Venous Thromboembolic Event (VTE)Prophylaxis in Medically III Patients (MAGELLAN)[EB OL].http:clinicaltrials.gov ct2 show NCT00571649.
[22] The Einstein-Extension Study.Once-Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism[EB OL].http: clinicaltrials.gov ct2 show NCT00439725.
[23] The RECORD1 Study Group.Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty[J].N Engl J Med, 2008, 358(26):2765-2775.
[24] Kakkar AK, Brenner B, Dahl OE, et al.Extended thromboprophylaxis with rivaroxaban compared with short-term thromboprophylaxis with enoxaparin after total hip arthroplasty: the RECORD 2 Trial [abstract] [J].Blood,2007, 110.
[25] RECORD3 Investigators.Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty[J].N Engl J Med, 2008, 358(26):2776-2786.
[26] Turpie A, Bauer K, Davidson B, et al.Comparison of rivaroxaban-an oral, direct factor Xa inhibitor--and subcutaneous enoxaparin for thromboprophylaxis after total knee replacement (RECORD4:a phase 3 study)[R].European Federation of National Associations of Orthopaedics and Traumatology 2008 Annual Meeting ;May 29-June 1,2008;Nice, France.Abstract F85.

新型抗凝药物直接Xa因子抑制剂利伐沙班

Novel anticoagulant, direct factor Xa inhibitor: Rivaroxaban

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	余巧玲, 翟葳葳, 刘平, 邱博, 吴惠珍. 利伐沙班血药浓度监测的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 809-817.
[2]	卢克鹏, 刘彩虹, 毕莹. 预防性抗凝持续时间对全髋/膝关节置换术后静脉血栓形成的影响[J]. 中国临床药理学与治疗学, 2023, 28(11): 1269-1274.
[3]	庞胜峰, 张晶, 吴宁宁, 李茹, 曹军, 何胜虎. 急性冠脉综合征患者PCI术后短程双联抗栓后单用替格瑞洛的疗效观察[J]. 中国临床药理学与治疗学, 2022, 27(9): 1004-1009.
[4]	邓毅凡, 何胜虎, 王大新, 戴承晔, 徐笑挺, 张晶. 依折麦布联合他汀对急性冠脉综合征行急诊介入患者残粒脂蛋白胆固醇及MACE影响的临床研究[J]. 中国临床药理学与治疗学, 2021, 26(9): 1048-1052.
[5]	石灿, 陈榕, 陈鹏姿, 吴甜. 腔静脉滤器在急性深静脉血栓形成患者系统溶栓治疗中的必要性探讨[J]. 中国临床药理学与治疗学, 2021, 26(12): 1413-1418.
[6]	龚小岭, 周海辉, 周玉皆. 胰腺癌静脉血栓栓塞病的研究进展[J]. 中国临床药理学与治疗学, 2021, 26(10): 1181-1185.
[7]	梅笛, 沈纪中, 刘春妍, 陆程灿, 徐伟, 彭宇竹. 新型口服抗凝药的药物基因组学研究进展[J]. 中国临床药理学与治疗学, 2021, 26(10): 1200-1207.
[8]	覃文杰, 杨志玲, 曹爱霖, 高航, 江冼芮, 沈越, 钱皎. 新型口服抗凝药在肿瘤相关性血栓栓塞的研究进展[J]. 中国临床药理学与治疗学, 2020, 25(7): 823-828.
[9]	杨蕾熙，冯凯，凡学婷，尉延春，刘婷婷，汤依群. 新化合物HYY-002抑制大鼠阵发性房颤作用[J]. 中国临床药理学与治疗学, 2019, 24(12): 1347-1352.
[10]	徐盛松，陶辉，石开虎，丁季飞. EZH2与α-SMA在风湿性心脏瓣膜病合并心房颤动患者心肌组织中的表达变化研究[J]. 中国临床药理学与治疗学, 2019, 24(12): 1371-1375.
[11]	张倩, 付红, 陈瑾瑾, 朱余兵. IL-33/ST2在急性冠脉综合征中的研究进展[J]. 中国临床药理学与治疗学, 2018, 23(9): 1075-1080.
[12]	郑琪娈，沈琪，余金聪，袁耀，陈波. 利伐沙班与血塞通注射液联合使用抑制脊柱术后下肢深静脉血栓形成的效果及血液指标的影响[J]. 中国临床药理学与治疗学, 2018, 23(3): 337-341.
[13]	陈刚，杨劲，张广钦. 华法林与胺碘酮相互作用研究进展[J]. 中国临床药理学与治疗学, 2017, 22(2): 215-221.
[14]	王世奇，胡烨文，陈晓敏，王健，叶红华 . 不同强度华法林在冠状动脉粥样硬化性心脏病并发心房颤动患者中的效果对比[J]. 中国临床药理学与治疗学, 2017, 22(12): 1410-1414.
[15]	张宁汝，张恒，李妙男，孙强，王洪巨，汤阳. 高血压合并急性冠脉综合征患者P₄₅₀2C19基因多态性与氯吡格雷抵抗及冠状动脉介入术后近期预后关系探讨[J]. 中国临床药理学与治疗学, 2016, 21(4): 425-431.